US4965288A
(en)
|
1988-02-25 |
1990-10-23 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4943593A
(en)
|
1988-02-25 |
1990-07-24 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5059714A
(en)
|
1988-02-25 |
1991-10-22 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5252608A
(en)
|
1988-02-25 |
1993-10-12 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5182297A
(en)
|
1988-02-25 |
1993-01-26 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5021456A
(en)
|
1988-02-25 |
1991-06-04 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5120764A
(en)
|
1988-11-01 |
1992-06-09 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4997854A
(en)
|
1989-08-25 |
1991-03-05 |
Trustees Of Boston University |
Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
AU1583397A
(en)
|
1996-01-30 |
1997-08-22 |
Brigham And Women's Hospital |
Antibodies for modulating cd47-mediated neutrophil transmigration
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
CA2226962A1
(fr)
|
1998-02-16 |
1999-08-16 |
Marie Sarfati |
Utilisation d'agents liants a cd47 et ces ligands pour le traitement ou prophylaxie de maladies inflammatoire, autoimmunitaire et allergique et pour le traitement de rejet de greffons
|
WO2001040307A1
(fr)
|
1999-11-30 |
2001-06-07 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Anticorps diriges contre les proteines regulatrices de signal
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
US7282556B2
(en)
|
2001-05-15 |
2007-10-16 |
Emory University |
Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
|
FR2828206B1
(fr)
|
2001-08-03 |
2004-09-24 |
Centre Nat Rech Scient |
Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US7841940B2
(en)
|
2003-07-14 |
2010-11-30 |
Astav, Inc |
Human test based on human conceptual capabilities
|
CN101133083A
(zh)
|
2003-11-11 |
2008-02-27 |
中外制药株式会社 |
人源化的抗cd47抗体
|
HUE030839T2
(en)
|
2004-05-13 |
2017-06-28 |
Icos Corp |
Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
JP5086809B2
(ja)
|
2004-12-17 |
2012-11-28 |
メルク カナダ インコーポレイテッド |
mPGES−1阻害剤としての2−(フェニルまたはヘテロ環式)−1H−フェナントロ[9,10−d]イミダゾール
|
US7442716B2
(en)
|
2004-12-17 |
2008-10-28 |
Merck Frosst Canada Ltd. |
2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
|
US20090142345A1
(en)
|
2005-03-15 |
2009-06-04 |
Takeda Pharmaceutical Company Limited |
Prophylactic/therapeutic agent for cancer
|
CN101223143A
(zh)
|
2005-05-18 |
2008-07-16 |
惠氏公司 |
作为tpl2激酶抑制剂的3-氰基喹啉以及其制备和应用方法
|
JP2008540667A
(ja)
|
2005-05-18 |
2008-11-20 |
ワイス |
Tpl2キナーゼの4,6−ジアミノ−[1,7]ナフチリジン−3−カルボニトリル阻害物質ならびにそれを製造および使用する方法
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
|
TW201402124A
(zh)
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
|
WO2007041635A2
(fr)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées
|
WO2007124589A1
(fr)
|
2006-05-02 |
2007-11-08 |
Merck Frosst Canada Ltd. |
Procédés permettant de traiter ou de prévenir des néoplasies
|
US20080131431A1
(en)
|
2006-05-15 |
2008-06-05 |
Viral Logic Systems Technology Corp. |
CD47 related compositions and methods for treating immunological diseases and disorders
|
IN2013MN00601A
(fr)
|
2006-05-22 |
2015-06-12 |
Univ California |
|
ITMI20061053A1
(it)
|
2006-05-30 |
2007-11-30 |
Manuli Rubber Ind Spa |
Raccordo per tubi flessibili per applicazioni oleodinamiche,industriali e aria condizionata,avente caratteristiche di tenuta migliorate.
|
DE102006058450A1
(de)
|
2006-12-12 |
2008-06-19 |
Eberhard-Karls-Universität Tübingen |
Zubereitungen zur Hemmung der Prostaglandin E2 Synthese
|
CN101784548B
(zh)
|
2007-06-29 |
2013-07-17 |
吉里德科学公司 |
嘌呤衍生物及其作为toll样受体7的调节剂的用途
|
CN103242444A
(zh)
|
2007-10-11 |
2013-08-14 |
大学健康网络 |
调节SIRPα-CD47相互作用以增加造血干细胞植入和用于此的化合物
|
TW200930368A
(en)
|
2007-11-15 |
2009-07-16 |
Astrazeneca Ab |
Bis-(sulfonylamino) derivatives in therapy
|
TW200930369A
(en)
|
2007-11-15 |
2009-07-16 |
Astrazeneca Ab |
Bis-(sulfonylamino) derivatives in therapy
|
US20090163586A1
(en)
|
2007-12-20 |
2009-06-25 |
Astrazeneca Ab |
Bis-(Sulfonylamino) Derivatives in Therapy 205
|
US20100324086A1
(en)
|
2008-02-19 |
2010-12-23 |
Novasaid Ab |
Compounds and methods
|
WO2009117987A2
(fr)
|
2008-03-26 |
2009-10-01 |
Universität Tübingen |
Utilisation d'acides de boswellia et de dérivés d'acides de boswellia synthétiques pour l'inhibition de la synthase de la prostaglandine e2 microsomale et de la cathepsine g
|
WO2009130242A1
(fr)
|
2008-04-23 |
2009-10-29 |
Novasaid Ab |
Dérivés à faible poids moléculaire et utilisation de ceux-ci dans le traitement de maladies associées à la prostaglandine e synthase
|
EP2119705A1
(fr)
|
2008-05-14 |
2009-11-18 |
AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. |
Composé 3-aminocarbozole, composition pharmaceutique le contenant et son procédé de fabrication
|
DE102008027331A1
(de)
|
2008-06-07 |
2009-12-10 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Verwendung von Indol-3-carbonsäureestern zur Hemmung der mikrosomalen Prostaglandin E2 Synthase
|
DE102008015432A1
(de)
|
2008-06-12 |
2009-12-17 |
Eberhard-Karls-Universität Tübingen |
Verwendung von Pirinixinsäure-Derivaten zur Hemmung der Prostaglandin E2 Synthese
|
DK2313111T3
(da)
|
2008-08-01 |
2013-12-02 |
Ventirx Pharmaceuticals Inc |
Toll-lignende receptoragonistformuleringer og anvendelse deraf
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
UY32138A
(es)
|
2008-09-25 |
2010-04-30 |
Boehringer Ingelheim Int |
Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
|
US8450321B2
(en)
|
2008-12-08 |
2013-05-28 |
Gilead Connecticut, Inc. |
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
|
CN103497192B
(zh)
|
2008-12-09 |
2015-09-23 |
吉里德科学公司 |
Toll样受体调节剂
|
CA2747678A1
(fr)
|
2008-12-19 |
2010-06-24 |
Novartis Ag |
Polypeptides solubles pour application au traitement de troubles auto-immuns et inflammatoires
|
WO2010083253A2
(fr)
|
2009-01-14 |
2010-07-22 |
Viral Logic Systems Technology Corp. |
Compositions associées au cd47 et procédés de traitement de maladies et de troubles immunologiques
|
UY32470A
(es)
|
2009-03-05 |
2010-10-29 |
Boehringer Ingelheim Int |
Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
|
TWI625121B
(zh)
|
2009-07-13 |
2018-06-01 |
基利科學股份有限公司 |
調節細胞凋亡信號之激酶的抑制劑
|
BR112012003757A2
(pt)
|
2009-08-18 |
2020-08-11 |
Ventirx Pharmaceuticals, Inc. |
benzoazepinas substituídas como moduladores de receptor tipo dobre de sino
|
DK2467380T3
(en)
|
2009-08-18 |
2017-03-13 |
Ventirx Pharmaceuticals Inc |
SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS
|
WO2011023812A1
(fr)
|
2009-08-27 |
2011-03-03 |
Novasaid Ab |
Inhibiteurs de prostaglandine e synthase-1 (mpges1) microsomale
|
AP3103A
(en)
|
2009-10-22 |
2015-01-31 |
Gilead Sciences Inc |
Derivatives of purine or deazapurine useful for the treatment of (inter alia)viral infections
|
WO2011048004A1
(fr)
|
2009-10-23 |
2011-04-28 |
Boehringer Ingelheim International Gmbh |
Inhibiteurs de la prostaglandine e2 synthase-1 microsomale
|
EP2516458A1
(fr)
|
2009-12-22 |
2012-10-31 |
Novartis AG |
Protéine hybride tétravalente à région constante d'anticorps anti-cd-47 à utiliser en thérapie
|
EP3181149A1
(fr)
|
2010-05-14 |
2017-06-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Anticorps monoclonaux humanisés et chimériques à cd47
|
WO2011146862A1
(fr)
|
2010-05-21 |
2011-11-24 |
Bellicum Pharmaceuticals, Inc. |
Méthodes d'induction d'une apoptose sélective
|
US8759537B2
(en)
|
2010-08-20 |
2014-06-24 |
Boehringer Ingelheim International Gmbh |
3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
|
US8586604B2
(en)
|
2010-08-20 |
2013-11-19 |
Boehringer Ingelheim International Gmbh |
Inhibitors of the microsomal prostaglandin E2 synthase-1
|
NZ701444A
(en)
|
2010-08-27 |
2016-06-24 |
Gilead Biologics Inc |
Antibodies to matrix metalloproteinase 9
|
CN103237549A
(zh)
|
2010-10-01 |
2013-08-07 |
帆德制药股份有限公司 |
过敏性疾病的治疗方法
|
KR101866893B1
(ko)
|
2010-10-01 |
2018-06-14 |
벤티알엑스 파마슈티칼스 인코포레이티드 |
Tlr 아고니스트의 치료적 용도 및 병용 요법
|
DK2649086T3
(en)
|
2010-12-09 |
2017-09-18 |
Univ Pennsylvania |
USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER
|
UY33779A
(es)
|
2010-12-10 |
2012-07-31 |
Boehringer Ingelheim Int |
?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
|
US8466186B2
(en)
|
2010-12-10 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Compounds
|
WO2012082647A2
(fr)
|
2010-12-13 |
2012-06-21 |
The Regents Of The University Of California |
Pyrazoles inhibiteurs de cox-2 et de seh
|
AR084174A1
(es)
|
2010-12-21 |
2013-04-24 |
Lilly Co Eli |
Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
|
AU2012205486B2
(en)
|
2011-01-12 |
2017-02-02 |
Array Biopharma, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
BR112013017947A2
(pt)
|
2011-01-12 |
2018-12-18 |
Array Biopharma Inc |
benzoazepinas substituídas como moduladores de receptor toll-like
|
WO2012110860A1
(fr)
|
2011-02-17 |
2012-08-23 |
Glenmark Pharmaceuticals S.A. |
Composés tricycliques en tant qu'inhibiteurs de mpges-1
|
BR122019023564B1
(pt)
|
2011-04-08 |
2021-06-22 |
Janssen Sciences Ireland Uc |
Formas de dosagem contendo derivados de pirimidina para o tratamento de infecções virais
|
LT2709989T
(lt)
|
2011-05-18 |
2018-04-10 |
Janssen Sciences Ireland Uc |
Chinazolino dariniai, skirti virusinių infekcijų ir kitų ligų gydymui
|
AR086254A1
(es)
|
2011-05-26 |
2013-11-27 |
Lilly Co Eli |
Derivados de imidazol utiles para el tratamiento de artritis
|
WO2012170250A1
(fr)
|
2011-06-07 |
2012-12-13 |
Radiation Control Technologies, Inc. |
Oligonucléotides morpholino aptes à inhiber un dommage cellulaire à médiation par cd47 et leurs utilisations
|
RU2632908C2
(ru)
|
2011-08-18 |
2017-10-11 |
Ниппон Синяку Ко., Лтд. |
Гетероциклическое производное и фармацевтическое средство
|
EP2749572A4
(fr)
|
2011-08-23 |
2015-04-01 |
Chugai Pharmaceutical Co Ltd |
Nouvel anticorps anti-ddr1 ayant une activité anti-tumorale
|
GB201115529D0
(en)
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
US20140235643A1
(en)
|
2011-10-04 |
2014-08-21 |
Gilead Calistoga Llc |
Novel quinoxaline inhibitors of pi3k
|
WO2013056352A1
(fr)
|
2011-10-19 |
2013-04-25 |
University Health Network |
Anticorps et fragments d'anticorps ciblant sirp-alpha et leur utilisation pour le traitement de cancers hématologiques
|
WO2013072825A1
(fr)
|
2011-11-16 |
2013-05-23 |
Glenmark Pharmaceuticals S.A. |
Dérivés de phtalazinone en tant qu'inhibiteurs de mpges-1
|
US8629274B2
(en)
|
2011-12-21 |
2014-01-14 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
JP6460796B2
(ja)
|
2012-01-17 |
2019-01-30 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
高親和性sirp−アルファ試薬
|
UY34573A
(es)
|
2012-01-27 |
2013-06-28 |
Gilead Sciences Inc |
Inhibidor de la quinasa que regula la señal de la apoptosis
|
WO2013116562A1
(fr)
|
2012-02-03 |
2013-08-08 |
Gilead Calistoga Llc |
Compositions et procédés de traitement d'une maladie avec (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phényl-3,4-dihydroquinazoline-2-yl)éthyl)amino)pyrimidine-5-carbonitrile
|
US20140140989A1
(en)
|
2012-02-06 |
2014-05-22 |
Inhibrx Llc |
Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
|
BR112014019331A2
(pt)
|
2012-02-06 |
2022-07-12 |
Inhibrx Inc |
anticorpos para cd47 e métodos de uso desses
|
EP2812331B1
(fr)
|
2012-02-08 |
2019-01-02 |
Janssen Sciences Ireland Unlimited Company |
Dérivés de la pipéridino-pyrimidine pour le traitement des infections virales
|
WO2013118071A1
(fr)
|
2012-02-09 |
2013-08-15 |
Glenmark Pharmaceuticals S.A. |
Composés bicycliques en tant qu'inhibiteurs de mpges-1
|
WO2013153535A1
(fr)
|
2012-04-13 |
2013-10-17 |
Glenmark Pharmaceuticals S.A. |
Composés tricycliques à titre d'inhibiteurs de la mpges-1
|
TWI568722B
(zh)
|
2012-06-15 |
2017-02-01 |
葛蘭馬克製藥公司 |
作爲mPGES-1抑制劑之三唑酮化合物
|
SG11201500814UA
(en)
|
2012-08-10 |
2015-03-30 |
Janssen Sciences Ireland Uc |
Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
|
UY35044A
(es)
|
2012-09-24 |
2014-04-30 |
Gilead Sciences Inc |
ANTICUERPOS ANTI-dDr1
|
HUE037064T2
(hu)
|
2012-10-10 |
2018-08-28 |
Janssen Sciences Ireland Uc |
Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére
|
US20150297573A1
(en)
|
2012-10-24 |
2015-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
|
BR112015011036B1
(pt)
|
2012-11-16 |
2022-02-01 |
Janssen Sciences Ireland Uc |
Derivados de 2-amino-quinazolina substituídos heterocíclicos, composição farmacêutica
|
CA3155275A1
(en)
|
2012-12-03 |
2014-06-12 |
Novimmune S.A. |
Anti-cd47 antibodies and methods of use thereof
|
WO2014093678A2
(fr)
|
2012-12-12 |
2014-06-19 |
Frazier William A |
Anticorps anti-cd47 thérapeutiques
|
LT2931752T
(lt)
|
2012-12-17 |
2019-12-10 |
Trillium Therapeutics Inc |
Ligos cd47+ ląstelių gydymas su sirp alfa-fc junginiais
|
WO2014100765A1
(fr)
|
2012-12-21 |
2014-06-26 |
Gilead Calistoga Llc |
Pyrimidine aminoalkyl-quinazolones substituées en tant qu'inhibiteurs de phosphatidylinositol 3-kinase
|
BR112015014592A2
(pt)
|
2012-12-21 |
2017-07-11 |
Gilead Calistoga Llc |
composto, composição farmacêutica, e, método para o tratamento de um humano
|
WO2014107171A1
(fr)
|
2013-01-07 |
2014-07-10 |
Omniox, Inc. |
Formes polymères de protéines h-nox
|
CN105189468B
(zh)
|
2013-02-21 |
2018-10-30 |
爱尔兰詹森科学公司 |
用于治疗病毒性感染的2-氨基嘧啶衍生物
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
EP2970493B1
(fr)
*
|
2013-03-15 |
2019-04-03 |
The Board of Trustees of the Leland Stanford Junior University |
Procédés d'obtention de doses thérapeutiquement efficaces d'agents anti-cd47
|
WO2014167444A1
(fr)
|
2013-04-08 |
2014-10-16 |
Glenmark Pharmaceuticals S.A. |
Composés bicycliques substitués utilisés en tant qu'inhibiteurs de mpges-1
|
AU2014277950B2
(en)
|
2013-06-14 |
2016-02-04 |
Gilead Calistoga Llc |
Phosphatidylinositol 3-kinase inhibitors
|
WO2015059618A1
(fr)
|
2013-10-22 |
2015-04-30 |
Glenmark Pharmaceuticals S.A. |
Composés de pyrimidine substitués utilisés en tant qu'inhibiteurs de mpges-1
|
US9290505B2
(en)
|
2013-12-23 |
2016-03-22 |
Gilead Sciences, Inc. |
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
|
SG11201607143UA
(en)
|
2014-03-11 |
2016-09-29 |
Univ Leland Stanford Junior |
Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
|
CN106163521B
(zh)
|
2014-03-27 |
2021-02-09 |
艾科西斯有限责任公司 |
有效的可溶性环氧化物水解酶抑制剂
|
MX2016013149A
(es)
|
2014-04-10 |
2017-04-27 |
Seattle Children's Hospital (Dba Seattle Children's Res Institute) |
Produccion de celulas t modificadas, mediante transposon bella durmiente, acoplada con seleccion por metotrexato.
|
US10081629B2
(en)
|
2014-04-14 |
2018-09-25 |
Jiangsu Hengrui Medicine Co., Ltd. |
Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof
|
CN113621075B
(zh)
|
2014-08-08 |
2024-09-20 |
Alx肿瘤生物技术公司 |
SIRP-α变体构建体及其用途
|
ES2962260T3
(es)
|
2014-08-08 |
2024-03-18 |
Univ Leland Stanford Junior |
Proteínas de fusión SIRPa alfa-anticuerpo
|
BR112017002646A2
(pt)
|
2014-08-15 |
2018-02-27 |
Merck Patent Gmbh |
proteínas de fusão da imunoglobulina sirp-alfa
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
JO3581B1
(ar)
|
2014-10-29 |
2020-07-05 |
Lilly Co Eli |
مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي
|
AR102361A1
(es)
|
2014-10-29 |
2017-02-22 |
Lilly Co Eli |
Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
|
EA201791093A1
(ru)
|
2014-11-18 |
2018-04-30 |
Янссен Фармацевтика Нв |
Антитела к cd47, способы и применение
|
WO2016090190A1
(fr)
|
2014-12-03 |
2016-06-09 |
Juno Therapeutics, Inc. |
Procédés et compositions pour thérapie cellulaire adoptive
|
EP3227337A1
(fr)
|
2014-12-05 |
2017-10-11 |
F. Hoffmann-La Roche AG |
Procédés et compositions de traitement du cancer à l'aide d'antagonistes de l'axe pd-1 et d'antagonistes de hpk1
|
AU2015362748A1
(en)
|
2014-12-15 |
2017-04-27 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled elimination of therapeutic cells
|
MX2017008819A
(es)
|
2014-12-30 |
2018-03-14 |
Celgene Corp |
Anticuerpos anti-cd47 y usos de los mismos.
|
TWI719966B
(zh)
|
2015-03-04 |
2021-03-01 |
美商索倫多醫療公司 |
結合cd47之抗體治療劑
|
AU2016232866B2
(en)
|
2015-03-17 |
2021-10-21 |
Omniox, Inc. |
Modulation of tumor immunity by protein-mediated 02 delivery
|
WO2016179399A1
(fr)
|
2015-05-06 |
2016-11-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Analogues du cd47 à haute affinité
|
EP3292152A1
(fr)
|
2015-05-07 |
2018-03-14 |
Agenus Inc. |
Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
|
CN104804093A
(zh)
|
2015-05-27 |
2015-07-29 |
江苏春申堂药业有限公司 |
一种针对cd47的单域抗体
|
AU2016271147B2
(en)
|
2015-05-29 |
2022-09-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
US10618976B2
(en)
|
2015-06-16 |
2020-04-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRP-α agonist antibody
|
LT3322711T
(lt)
|
2015-06-25 |
2021-05-10 |
University Health Network |
Hpk1 inhibitoriai ir jų panaudojimo būdai
|
EP3913051A1
(fr)
|
2015-08-07 |
2021-11-24 |
ALX Oncology Inc. |
Constructions de variant sirp-alpha et utilisations associées
|
KR20180051625A
(ko)
|
2015-09-17 |
2018-05-16 |
노파르티스 아게 |
증진된 효능을 갖는 car t 세포 요법
|
NZ740686A
(en)
|
2015-09-18 |
2021-12-24 |
Arch Oncology Inc |
Therapeutic cd47 antibodies
|
CN108290948B
(zh)
|
2015-09-21 |
2021-10-29 |
伊拉兹马斯大学医疗中心 |
抗-cd47抗体及使用方法
|
WO2017096281A1
(fr)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
AU2016364895A1
(en)
|
2015-12-02 |
2018-06-07 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
WO2017096276A1
(fr)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anticorps anti-gitr et procédés d'utilisation associés
|
JP7089470B2
(ja)
|
2015-12-02 |
2022-06-22 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
US20200079862A1
(en)
|
2015-12-03 |
2020-03-12 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
EP4253412A3
(fr)
|
2015-12-16 |
2023-11-22 |
The Walter and Eliza Hall Institute of Medical Research |
Inhibition de protéines sh2 induites par des cytokines dans des cellules nk
|
SG11201805894YA
(en)
|
2016-01-11 |
2018-08-30 |
Forty Seven Inc |
Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
|
WO2017147410A1
(fr)
|
2016-02-25 |
2017-08-31 |
Amgen Inc. |
Composés inhibant la protéine mcl-1
|
WO2017160861A1
(fr)
|
2016-03-15 |
2017-09-21 |
The Regents Of The University Of California |
Inhibiteurs de l'hydrolase d'époxyde soluble (seh) et de l'hydrolase d'amide d'acides gras (faah)
|
SG11201808465UA
(en)
|
2016-04-14 |
2018-10-30 |
Ose Immunotherapeutics |
NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
|
CN115785272A
(zh)
|
2016-04-14 |
2023-03-14 |
Ose免疫疗法 |
新型抗-SIRPa抗体及其治疗应用
|
CN109195634A
(zh)
|
2016-04-15 |
2019-01-11 |
延龄草疗法有限公司 |
Cd47阻断治疗中的巨噬细胞刺激
|
TW201741340A
(zh)
|
2016-05-09 |
2017-12-01 |
賽基公司 |
Cd47抗體及使用其之方法
|
EP3243522A1
(fr)
|
2016-05-10 |
2017-11-15 |
Université Pierre et Marie Curie (Paris 6) |
Agents agonistes de cd47 induisant la mort cellulaire programmée et leur utilisation dans les traitements de maladies associées à des défauts dans la mort cellulaire programmée
|
AU2017276457B2
(en)
|
2016-06-07 |
2019-10-03 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel heterocyclic derivatives useful as SHP2 inhibitors
|
CN106084052B
(zh)
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
AU2017289158C1
(en)
|
2016-06-30 |
2020-07-23 |
Gilead Sciences, Inc. |
4,6-diaminoquinazolines as Cot modulators and methods of use thereof
|
CA3031034A1
(fr)
|
2016-08-03 |
2018-02-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
L'interruption de l'engagement du recepteur fc sur les macrophages ameliore l'efficacite de la therapie par anticorps anti-sirpalpha
|
US20180072718A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
TW201811799A
(zh)
|
2016-09-09 |
2018-04-01 |
美商英塞特公司 |
吡唑并嘧啶化合物及其用途
|
WO2018049191A1
(fr)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Dérivés de pyrazolopyridone en tant que modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
|
EP3510032B1
(fr)
|
2016-09-09 |
2022-07-06 |
Incyte Corporation |
Dérivés de pyrazolopyridine en tant que modulateur de hpk1 pour le traitement du cancer
|
EP3512519A1
(fr)
|
2016-09-14 |
2019-07-24 |
Gilead Sciences, Inc. |
Inhibiteurs de syk
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
GB2605540B
(en)
|
2016-10-18 |
2022-12-21 |
Univ Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
BR112019008010A2
(pt)
|
2016-10-20 |
2019-07-09 |
I Mab |
anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
|
EP3529276A4
(fr)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
Anticorps cd47 thérapeutiques
|
WO2018089508A2
(fr)
|
2016-11-08 |
2018-05-17 |
Ablexis, Llc |
Anticorps anti-cd47
|
AU2017359467A1
(en)
|
2016-11-09 |
2019-05-02 |
Agenus Inc. |
Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
|
TW201819413A
(zh)
|
2016-11-28 |
2018-06-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Cd47抗體、其抗原結合片段及其醫藥用途
|
US11180482B2
(en)
|
2016-11-30 |
2021-11-23 |
Ariad Pharmaceuticals, Inc. |
Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
|
SG10201912879YA
(en)
|
2016-12-09 |
2020-02-27 |
Alector Llc |
Anti-sirp-alpha antibodies and methods of use thereof
|
AU2018213718B2
(en)
|
2017-01-26 |
2022-08-25 |
Zlip Holding Limited |
CD47 antigen binding unit and uses thereof
|
JP7132937B2
(ja)
|
2017-03-15 |
2022-09-07 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Hpk1の阻害剤としてのアザインドール
|
EA202190196A1
(ru)
|
2017-03-23 |
2021-08-31 |
Джакобио Фармасьютикалс Ко., Лтд. |
Новые гетероциклические производные, применимые в качестве ингибиторов shp2
|
KR20190136028A
(ko)
|
2017-03-30 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
Hpk1 억제제로서의 나프티리딘
|
JP6453507B2
(ja)
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Mcl−1タンパク質を阻害する化合物
|
CN117024411A
(zh)
|
2017-03-30 |
2023-11-10 |
豪夫迈·罗氏有限公司 |
作为hpk1抑制剂的异喹啉
|
CA3058134A1
(fr)
|
2017-04-13 |
2018-10-18 |
Aduro Biotech Holdings, Europe B.V. |
Anticorps anti-sirp alpha
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
DK3625259T3
(da)
|
2017-05-16 |
2024-07-08 |
Byondis Bv |
Anti-sirpalpha-antistoffer
|
CN109096395B
(zh)
|
2017-06-20 |
2022-06-24 |
华兰生物工程股份有限公司 |
阻断型cd47纳米抗体及其用途
|
US11141480B2
(en)
|
2017-06-21 |
2021-10-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Dosing parameters for CD47 targeting therapies to hematologic malignancies
|
PL3658589T3
(pl)
|
2017-07-26 |
2024-03-18 |
Forty Seven, Inc. |
Przeciwciała anty-sirp-alfa i powiązane sposoby
|
CN111183155B
(zh)
|
2017-08-02 |
2024-02-20 |
凡恩世制药(北京)有限公司 |
抗cd47抗体及其用途
|
JP7256580B2
(ja)
|
2017-08-18 |
2023-04-12 |
ウルトラヒューマン フォー リミティド |
結合剤
|
CN109422811A
(zh)
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
CN108503708B
(zh)
|
2017-09-01 |
2021-07-30 |
北京智仁美博生物科技有限公司 |
抗人cd47抗体及其用途
|
CN109422726B
(zh)
|
2017-09-04 |
2022-10-28 |
华东理工大学 |
CD47/SIRPα的阻断剂及其应用
|
KR20200079511A
(ko)
|
2017-11-01 |
2020-07-03 |
허밍버드 바이오사이언스 홀딩스 피티이. 엘티디. |
Cd47 항원-결합 분자
|
WO2019103203A1
(fr)
|
2017-11-24 |
2019-05-31 |
주식회사 젬백스앤카엘 |
Nouveau peptide et composition le comprenant
|
CN111448213A
(zh)
|
2017-12-01 |
2020-07-24 |
西雅图基因公司 |
Cd47抗体及其用于治疗癌症的用途
|
SG11202005992XA
(en)
|
2018-01-12 |
2020-07-29 |
Aurigene Discovery Tech Ltd |
1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
|
SG11202006877PA
(en)
|
2018-01-24 |
2020-08-28 |
Nanjing Legend Biotech Co Ltd |
Anti-cd47 antibodies that do not cause significant red blood cell agglutination
|
SI3752501T1
(sl)
|
2018-02-13 |
2023-08-31 |
Gilead Sciences, Inc. |
Inhibitorji pd-1/pd-l1
|
CN110144009B
(zh)
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
WO2019173692A2
(fr)
|
2018-03-09 |
2019-09-12 |
Agenus Inc. |
Anticorps anti-cd73 et leurs procédés d'utilisation
|
CN112105646A
(zh)
|
2018-03-13 |
2020-12-18 |
Ose免疫疗法 |
抗人SIRPa v1抗体的用途和生产抗SIRPa v1抗体的方法
|
WO2019179366A1
(fr)
|
2018-03-20 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Nouveaux anticorps anti-cd47
|
WO2019183266A1
(fr)
|
2018-03-21 |
2019-09-26 |
ALX Oncology Inc. |
Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
CN110305212A
(zh)
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
CN110386984B
(zh)
|
2018-04-17 |
2022-04-22 |
杭州尚健生物技术有限公司 |
结合cd47蛋白的融合蛋白及其应用
|
KR20210005240A
(ko)
|
2018-05-03 |
2021-01-13 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
면역 관문 차단과 함께 키메라 항원 수용체를 발현하도록 가공된 천연 킬러 세포
|
PL3793565T3
(pl)
|
2018-05-14 |
2022-05-02 |
Gilead Sciences, Inc. |
Inhibitory MCL-1
|
CN110577597B
(zh)
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技(成都)有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
CN112566662A
(zh)
|
2018-06-15 |
2021-03-26 |
阿库鲁斯生物科学公司 |
针对cd47的阻断抗体及其使用方法
|
EP3817769A4
(fr)
|
2018-07-05 |
2022-03-30 |
Trican Biotechnology Co., Ltd |
Anticorps anti-cd47 humains et leurs utilisations
|
CN117024593A
(zh)
|
2018-07-10 |
2023-11-10 |
国立大学法人神户大学 |
抗SIRPα抗体
|
TWI809427B
(zh)
|
2018-07-13 |
2023-07-21 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
WO2020019135A1
(fr)
|
2018-07-23 |
2020-01-30 |
中国科学院微生物研究所 |
Anticorps anti-cd47 et son utilisation
|
EP3836960A4
(fr)
|
2018-08-13 |
2022-05-11 |
Arch Oncology, Inc. |
Anticorps cd47 thérapeutiques
|
EP3845561A4
(fr)
|
2018-08-31 |
2022-07-06 |
Nanjing Sanhome Pharmaceutical Co., Ltd. |
Anticorps anti-cd47 et son utilisation
|
CA3113798A1
(fr)
|
2018-09-27 |
2020-04-02 |
Celgene Corporation |
Proteines de liaison sirpa et methodes d'utilisation de celles-ci
|
WO2020092621A1
(fr)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Composés de 6-azabenzimidazole substitués en tant qu'inhibiteurs de hpk1
|
US11071730B2
(en)
|
2018-10-31 |
2021-07-27 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds
|
TW202124450A
(zh)
|
2019-10-18 |
2021-07-01 |
美商四十七股份有限公司 |
用於治療骨髓發育不良症候群及急性骨髓白血病之組合療法
|